May 8, 2018 / 8:14 PM / 6 months ago

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

May 8 (Reuters) - Arena Pharmaceuticals Inc:

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

* Q1 LOSS PER SHARE $0.80

* Q1 REVENUE VIEW $2.8 MILLION -- THOMSON REUTERS I/B/E/S

* Q1 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below